

Intermittent Pneumatic Compression & Compliance Monitoring

Flowtron® ACS900 System

Authors: **Jonathan Busby**, MSc, BSc (Hons) RN. Director Global Medical Affairs.
EUR ING **David Newton**, M.Eng, C.Eng, MIET, MIEEE. Product Development Manager.

Introduction & clinical context

Venous Thromboembolism (VTE) is a complex vascular disease that encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). A DVT develops most commonly in the deep veins of the calf, thigh and pelvis and becomes symptomatic when the clot limits blood flow (Figure 1).




Figure 1: Formation of a Deep Vein Thrombosis (DVT)

A more serious condition is pulmonary embolism (PE) where part of, or all of the thrombus in the limb breaks off and enters the pulmonary arterial circulation, occluding blood flow to the lungs (Figure 2). If the embolism is large, it can be fatal.




Figure 2: Pulmonary Embolism

VTE formation, although complex, depends on three key principles known collectively as Virchow's triad namely: Venous Stasis, Hypercoagulation and Vessel Injury (Figure 3). These factors come into play most commonly during periods of immobility (any cause), trauma and surgery or from a genetic predisposition to thrombophilia.




Figure 3: Virchow's Triad

Population incidence and consequence of VTE

Approximately 10 million cases of VTE are reported worldwide each year¹, with VTE posing a significant safety issue for hospitalised patients^{2,3}. Sadly, around 30% of patients will die within 30 days of a VTE event, whilst 25% of unexpected inpatient deaths are only diagnosed with a PE at autopsy⁴. Aside from acute VTE, almost one third of patients go on to develop post thrombotic syndrome, suffering swelling and pain; in 25% of cases this leads to chronic recalcitrant leg ulceration⁴.

Economic impact of VTE

VTE, the second most common complication of hospitalisation worldwide after adverse drug events¹, adds a significant financial burden to stretched health care systems^{2,5,6,7,8}. For example, the USA spends up to \$10 billion each year on VTE⁷, while Europe has been estimated to spend up to €8.5 billion, of which up to €6.2 billion may be considered avoidable⁹. Alongside high financial cost is the human cost, with VTE a leading cause of morbidity and mortality accounting for around 7% of deaths in Australian hospitals¹⁰ and 12,000 deaths each year in England¹¹. The need to reduce the incidence of VTE is compelling particularly as VTE can be largely avoided¹.

Preventing VTE

National and international evidence-based guidelines strongly support the use of routine thromboprophylaxis for vulnerable individuals¹²⁻¹⁹. The guidance considers such interventions to be cost-effective in bringing a reduction in mortality and adverse patient outcomes, many of which would otherwise be life-changing. Prevention strategies for VTE commonly incorporate the use of pharmacological prophylaxis (anticoagulant, antiplatelet) and mechanical methods including Intermittent Pneumatic Compression (IPC). These can be used as stand-alone therapies or, for the highest risk patients, used in combination for enhanced benefit¹⁴.

Intermittent Pneumatic Compression

Intermittent Pneumatic Compression consists of a range of garments, typically applied to the foot, calf or calf and thigh, which are intermittently inflated and deflated by means of a powered pump (Figure 4). This technology represents a well-established strategy for VTE prevention¹²⁻¹⁹.



Figure 4: Flowtron ACS900 & garment range

All IPC systems have the same principle objective and that is to squeeze blood from the underlying deeper veins of the leg causing it to be displaced in a proximal direction¹⁹. With simple, yet effective, external compression, IPC mimics the natural activity of the ambulatory calf muscle pump. The effect causes increased blood flow velocity in the deep veins, reduced stasis and a flushing effect on venous valve pockets where thrombi may originate.

In addition to a localised effect, the increased blood flow also creates a shear strain on the endothelial lining of the blood vessels causing biochemical mediators to be released globally: this further hinders clot formation, while enhancing fibrinolysis, platelet disaggregation and vasodilation^{20,21}. IPC therefore directly and safely addresses two of the three causative factors associated with VTE formation - venous stasis and hypercoagulation (Figure 3) without increasing the risk of haemorrhage.

Recommendations on IPC use

In order to achieve optimum VTE prevention, continuous use of IPC therapy is recommended for at least 72 hours or until the patient is fully mobile; it is also recommended that continuous wear time is a minimum of 18 hours/day¹².

Factors affecting adherence to IPC protocol

Despite multiple trials demonstrating the efficacy of IPC in preventing VTE events, non-compliance remains the principal barrier to IPC effectiveness²². Considerable variability in adherence has been reported^{23,24,25,26} with compliance rates as low as 0-19%^{19,24}. Reasons given include, pump not available, pump not working and, important for compliance-monitoring, garments not fitted correctly or at all. Similarly, a systematic review of seven studies in acute care reported a median adherence rate of 78% (range 40%-89%)²³ while a study of 123 mechanically ventilated patients found a misapplication rate of 50 percent²⁵. Given that concordance with IPC therapy is linked to positive outcomes, it is important that clinicians can accurately identify interruption in therapy. Guidelines therefore recommend that IPC devices facilitate recording and reporting of proper wear time for both inpatients and outpatients²⁷.

Flowtron[®] ACS900 with Compliance Monitoring

The Flowtron ACS900 system delivers both uniform and sequential compression therapy across a range of lower limb garments that can be used alone or in combination. For safety, SmartSense™ garment detection (Arjo[®]) automatically sets the correct pressure and compression cycle without the need for any additional user intervention, while compliance-monitoring software displays the actual wear time (Figure 5).

If the garment is removed, in addition to an audio-visual alarm, the elapsed 'non-compliant' time is displayed on the pump. This enables the clinician to check and accurately document concordance with prescribed therapy, including cumulative 'wear time' over the course of an individual patient care episode.



Figure 5: Flowtron ACS900 with compliance monitoring feature

In developing this Compliance Monitoring feature, stringent control and validation tests were carried out to ensure 'wear time' and 'lapsed time' data were accurate (quantitative), easily accessed (qualitative) by the end user and with a performance that matched or exceeded other 'smart' IPC systems in clinical use (control device). The results of these performance validation tests follow.

Compliance monitoring: Measuring accuracy

Aim

To evaluate the performance of the compliance-monitoring feature in the Flowtron ACS900 when used with a range of uniform and sequential compression lower limb garments.

Primary objective

- Determine whether the device accurately records the presence (and absence) of a limb in a garment
- Compare the performance of the Flowtron ACS900 compliance-monitoring feature with a proprietary benchmark

Secondary objective

- Determine whether 'no garment fitted' alarms are activated appropriately (time, audio, visual) and the pump displays run/restart as expected

Methodology

Test subject

Four uniform compression garments (DVT60, DVT30, DVT 10, DVT5) and two TriPulse™ sequential garments (TRP60, TRP30) powered by the Flowtron ACS900 IPC device (Arjo®). Compliance alarms (no garment or limb fitted) are intended to automatically reset when the garment is reapplied.

Control

Two adjustable sequential compression garments (calf/thigh, calf) and intermittent compression pump from an alternative supplier. Compliance alarms (no garment fitted) required a manual reset when the garment is reapplied.

Both pumps were in calibration and set up in line with the manufacturers' instructions and the compliance-monitoring features cleared of all previous data and reset. Garments were fitted as recommended by the manufacturer and the same test (human) volunteers used across both the test and control conditions to avoid inter-subject variability.

Across a series of test interventions, garments were removed and reapplied to the limbs to a predefined schedule (Figure 6): each test series ran for 105 minutes. This schedule is intended to demonstrate usage found in a typical clinical setting. It includes both longer and shorter periods of use and non-use that are associated with patient and clinical activities and so represent a real life challenge to the pump timing.




Figure 6: Test protocol

Garment applied (compliant) and lapsed (non-compliant / no garment) time from the individual pump displays were captured. In addition, an observer recorded garment compliance and whether the alarm conditions were triggered and reset as outlined in the user manuals.

At the end of each test run device-reported compliance (pump data) were compared to expected compliance (actual wear time). Once all results were collated statistical analysis (Mann Whitney U test) was used to determine comparative performance between the Flowtron ACS900 IPC system and the control device.

Results

Flowtron ACS900 IPC system

The pumps detected the presence or otherwise of a garment at the point of inflation. If the garment was still being removed or replaced during the inflation cycle it was picked up within 60 seconds at the next inflation cycle giving a maximum error time of ±1 minute. In all cases the alarms activated when they should, the pump continued to run during the alarm condition and the alarms stopped automatically upon reattaching the garments. For each combination of garments the total wear time was 50 minutes (Table 1).

- **Average recorded wear time was 48.7 (range 47-51) minutes, which is an accuracy of 97.3%.**

Control device

The 'garment-off' alarm was activated 5 minutes after garment removal in each test series and stopped only when reset by the operator at the point of garment reapplication. Average recorded wear time was, in all cases, longer than actual garment application (Table 1). At the upper range, garment wear time was recorded at 75 minutes, which is 50% greater than actual wear time (50 minutes).

- **Average recorded wear time was 66.7 (range 63-75) minutes, which is an accuracy of 66.5%.**

The two datasets were compared using a Mann Whitney U test and revealed a significant difference in the performance of both pumps. With regard to compliance monitoring, the Flowtron ACS900 IPC system has been shown to be the more accurate device ($p < 0.0036$) with pump-recorded wear time closely representing actual wear time.

Compliance Monitoring: Usability

While technical bench testing is an important validation step for product development, the device must also have a high level of usability, because a product that is difficult to use will undoubtedly lead to lower compliance and increases the risk of misuse. Getting end user feedback is critical to the evolution of a class-leading device.

Aim

To evaluate the usability and acceptability of the compliance-monitoring feature in the Flowtron ACS900, when used with a range of uniform and sequential compression lower limb garments, and monitored by minimally trained healthcare staff.

Primary objective

- Determine whether minimally trained users can correctly identify alarm conditions
- Determine whether minimally trained users can correctly record non-compliant time (garment removed)
- Determine whether minimally trained users can correctly record the total compliant (therapy) time

Methodology

A minimum of six nurses or other healthcare professionals, familiar with the Flowtron ACS900 IPC system or similar IPC devices, were invited to participate; the evaluation took place within a hospital stroke unit. Participants were invited to read the troubleshooting section of the Instructions for Use (IFU) and a period of at least 60 minutes minimum between reading the IFU and carrying out the task was enforced to allow for learning decay.

TEST CONDITION	FLOWTRON ACS900	CONTROL	MANN WHITNEY U TEST
50 minutes (wear time)	48.7 (range 47-51)	66.7 (range 63-75)	p=<0.0036
Accuracy	97.33%	66.5%	

Table 1: Compliance monitoring accuracy

USABILITY GOAL	GOAL	ACCEPTANCE CRITERIA	RESULTS	PASS/FAIL
1	Minimally trained users shall be able to identify the alarm correctly.	95%	100%	PASS
2	Minimally trained users shall be able to identify the time the leg hasn't been in the garment correctly.	80%	100%	PASS
3	Minimally trained users shall be able to identify the duration of therapy delivered correctly.	80%	100%	PASS

Table 2: Usability performance goals

The Flowtron ACS900 IPC system was set up according to the manufacturer's instructions and a DVT 10 garment fitted. Participants were asked to leave the room before and between tests and, on return, were presented with three different scenarios (below). Each was asked to correctly identify therapy status from the alarm indicators and record the duration of compliance / non-compliance with therapy.

- Garment has been unplugged from the pump
- Garment has been removed from the leg [non-compliance time]
- Garment fitted correctly and pump in normal therapeutic mode [compliance time]

An independent observer recorded participant responses and pass-fail usability benchmarks were set as shown in Table 2

Results

Six healthcare professionals participated across a range of disciplines including staff nurses, a nurse specialist, an educator, an occupational therapist and a medical engineer. All were familiar with Arjo IPC systems and had between three weeks and sixteen years experience.

In all test conditions the six participants correctly identified and addressed the simulated faults and were able to determine the duration of either therapy or non-compliance. Five of the six individuals disconnected the garment from the pump before reapplying to the limb and then reconnecting to the pump (quoted: 'easier to remove residual air'). The least experienced clinician reapplied the garment without pump disconnection and, in all cases, normal therapy resumed without further intervention or need to interact with the pump. Anecdotally, all reported that they refit and plug in the garment without stopping the pump, benefiting from automatic functionality.

Summary

Technical bench tests are an important step in the validation of product features, particularly when assessing clinical utility and safety. Where a European or International performance standard has not been defined, it is appropriate to compare performance against an established device that has substantial market presence and acknowledged clinical efficacy. The findings of the modest test series presented here shows the Flowtron ACS900 IPC device triggers appropriate alarms to alert the caregiver to garment removal and records total wear time with a level of accuracy that is clinically appropriate and does not overestimate therapy compliance. In addition, the device automatically cancels the alarms when the garment is reapplied, a welcome usability feature for the busy healthcare environment.

A device also has to be easy to use and accessible in order to be of benefit in a busy healthcare environment. Features such as audio-visual alarms and longitudinal compliance monitoring can flag therapy interruptions, such as delayed initiation and garment removal, which have been identified as a major barrier to compliance^{5,24,25,28,29}. The simple usability study reported above was able to confirm that the compliance-monitoring feature is an intuitive extension of the standard alarm system on the Flowtron ACS900 IPC and enables caregivers to accurately assess both therapy duration and periods of non-compliance.

Conclusion

The ability to monitor patient wear time during IPC therapy and provide patient specific data related to concordance with mechanical prophylaxis is an important component of the VTE care pathway. Validation and usability testing has shown the Flowtron ACS900 IPC device monitors compliance and does so with a level of accuracy and usability that significantly exceeds that of the benchmark competitive Sequential Compression Device.

References

1. Jha AK, Larizgoitia I, Audera-Lopez C, et al. The global burden of unsafe medical care: Analytic modelling of observational studies. *BMJ Qual Saf*. 2013;22:809-15
2. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. *Arch Intern Med* 2000; 160:809-15.
3. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med* 2002; 162:1245-8.
4. Beckman MG, Hooper WC, Critchley SE et al. Venous thromboembolism: a public health concern. *Am J Prev Med*. 2010; 38(4):S495-501.
5. Ritesma DF, Watson JM, Stiteler AP et al. Sequential compression devices in postoperative urologic patients: an observational trial and survey study on the influence of patient and hospital factors on compliance. *BMC Urology* 2013, 13:20. <http://www.biomedcentral.com/1471-2490/13/20>. Last accessed December 2021.
6. Saunders R, Comerota AJ, Ozuls A et al. Intermittent pneumatic compression is a cost effective method of orthopaedic post-surgical venous thromboembolism prophylaxis. *Clinico Economics and Outcomes Research*. 2018; 10:231-241
7. Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of venous thromboembolism in the United States: A review of estimated attributable healthcare costs. *Thromb Res*, 2016 Jan; 137:3-10. Doi:10.1016/j.thromres.2015.11.033
8. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. *J Med Econ*. 2011; 14(1): 65-74
9. Barco S, Woerschling AL, Spyropoulos AC et al. European Union-28: an annualised cost-of-illness model for venous thromboembolism. *Thromb Haemost*. 2016; 115(4):800-808.
10. Access Economics. The burden of venous thromboembolism in Australia. Report for the Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. 2008
11. NHS Digital. 5.1 deaths from venous thromboembolism (VTE) related events within 90 days post discharge from hospital, 2019. Available: [https:// digital.nhs.uk/](https://digital.nhs.uk/) Last accessed December 2021.
12. Guyatt GH, Akl EA, Crowther M et al. For the American College of Chest Physicians. Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):7S-47S
13. National Institute for Clinical Excellence. Venous Thromboembolism: Reducing the risk of VTE in patients admitted to hospital. 2010. Available at: www.nice.org.uk/guidance/CG92
14. Kakkos SK, Caprini JA, Geroulakos G et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Cochrane Database of Systematic Reviews*. 2008; issue 4, CD005258
15. Zhao J, HE M, Xiao Z et al. Different types of Intermittent Pneumatic Compression devices for preventing venous thromboembolism in patients after total hip replacement. *Cochrane Database of Systematic Reviews*, November 2014;11:CD009543
16. Liew N, Chang Y, Choi G et al. Asian Venous Thromboembolism Guidelines: Prevention of venous thromboembolism. *International Angiology*. 2012; 31(6):501-16
17. Ho K, Tan J. Stratified meta-analysis of Intermittent Pneumatic Compression of the lower limbs to prevent venous thromboembolism in hospitalised patients. *Circulation*. 2013; 128:1003-1020
18. National Institute for Health & care Excellence 2018. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Available at: www.nice.org.uk/guidance/ng89. Last Accessed December 2021
19. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133 (suppl): 381S-453S
20. Chen A, Frangos S, Kilaru S et al. Intermittent pneumatic compression devices - Physiological mechanisms of action. *European Journal of Vascular and Endovascular Surgery*. 2001; 21:383-392
21. Giddings JC, Ralis H, Jennings G et al. Suppression of the tissue factor pathway combined with enhanced tissue plasminogen activator activity 9tPA) and urokinase plasminogen activator (scuPA) after intermittent pneumatic compression. *Supplement to the Journal Thrombosis and Haemostasis*. 2001; 86:2240
22. Obi At, Alvarez R, Reames BN et al. A prospective evaluation of standard versus battery-powered sequential compression devices in postsurgical patients. *Am J Surg*. 2015; 209(4):675-618
23. Craigie S, Tsui JF, Agarwal A, et al. Adherence to mechanical thromboprophylaxis after surgery: a systematic review and meta-analysis. *Thromb Res* 2015;136:723-6.
24. Cornwell, E.E., III, Chang, D., Velmahos, G. et al. Compliance with sequential compression device prophylaxis in at risk trauma patients: A retrospective Analysis. *American Surgeon*. 2002; 68(5): 470-473
25. Elpern E, Killeen K, Patel G et al. The application of IPC compression devices for thromboprophylaxis. *American Journal of Nursing*. 2013; 113 (4):30-36
26. Elpern E, Killeen K, Patel G, et al. The application of intermittent pneumatic compression devices for thromboprophylaxis: an observational study found frequent errors in the application of these mechanical devices in ICUs. *Am J Nurs* 2013;113:30-6.
27. ACCP 9th Edition in Orthopaedic Surgery
28. Maxwell GL, Synan I, Hayes RP, et al. Preference and compliance in postoperative thromboembolism prophylaxis among gynecologic oncology patients. *Obstet Gynecol* 2002;100:451-5.
29. Brady D, Raingruber B, Peterson J, et al. The use of knee-length versus thigh-length compression stockings and sequential compression devices. *Crit Care Nurs Q* 2007;30:255-62.

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With over 6000 people worldwide and 60 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges.

Arjo AB • Hans Michelsensgatan 10 • 211 20 Malmö • Sweden • +46 10 335 4500

www.arjo.com